
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is a commercial-stage medical device company that develops and sells the iLet Bionic Pancreas, the first FDA-cleared closed-loop insulin delivery device on the market. The company's strong Q1 results, increased guidance, and expansion of its sales force indicate a positive outlook for its financial performance and future market share in the diabetes sector. Despite a recent FDA Warning Letter, the company remains confident in its ability to continue operations and bring its innovative products to market. This, coupled with a promising innovation pipeline, suggests a strong potential for growth and makes BBNX a top choice for investors looking for a fast-growing MedTech company.
Bears say
Beta Bionics is seen as a high-risk investment due to slower revenue growth compared to its SMID growth peers and a recent decline in NPS momentum. This has resulted in multiple compression and a decrease in the stock price. The company's future prospects remain unclear, with potential overhangs related to management execution and a pending WL decision. However, the stock may offer a favorable risk-reward opportunity in the long term, once NPS momentum improves and there is progress on the MINT regulatory submission.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares